ReviewAsian journal of urology2019
If this is true, what does it imply? How end-user antibody validation facilitates insights into biology and disease.
Review in Asian journal of urology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 32 citations in OpenAlex.
- Tumor Cholesterol Synthesis, Statin Use, and Lethal Prostate Cancer.Molecular cancer research : MCR · 2025Article
- Antibody-Based Multiplex Image Analysis: Standard Analytical Workflows and Artificial Intelligence Tools for Pathologists.Laboratory investigation; a journal of technical methods and pathology · 2025Review
- Article
- Prevalence of Mismatch Repair Deficiency in Primary Prostate Cancer in a Large Prospective Cohort.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- Computational methods and biomarker discovery strategies for spatial proteomics: a review in immuno-oncology.Briefings in bioinformatics · 2024Review
- Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer.Molecular cancer therapeutics · 2024Article
- Novel ALK immunohistochemistry assay (clone OTI1A4, Dako) is a sensitive, reliable marker for identifying ALK rearrangements in lung adenocarcinomas: A validation study.American journal of clinical pathology · 2024Article
- Characterization of HOXB13 expression patterns in localized and metastatic castration-resistant prostate cancer.The Journal of pathology · 2024Article
- PACInternational journal of molecular sciences · 2022Article
- Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Article
- A review of reproducible and transparent research practices in urology publications from 2014 to2018.BMC urology · 2022Review
- Overcoming stromal barriers to immuno-oncological responses via fibroblast activation protein-targeted therapy.Immunotherapy · 2021Article
- AR-V7 biomarker testing for primary prostate cancer: The ongoing challenge of analytical validation and clinical qualification.Cancer treatment and research communications · 2021Article
- Putative Autoantigen Leiomodin-1 Is Expressed in the Human Brain and in the Membrane Fraction of Newly Formed Neurons.Pathogens (Basel, Switzerland) · 2020Article
- Enhanced Validation of Antibodies Enables the Discovery of Missing Proteins.Journal of proteome research · 2020Article
- Antibody validation for protein expression on tissue slides: a protocol for immunohistochemistry.BioTechniques · 2020Article
- [RNA in situ hybridization: technology, potential, and fields of application].Der Pathologe · 2020Review
- PIM kinase inhibition: co-targeted therapeutic approaches in prostate cancer.Signal transduction and targeted therapy · 2020Review
- Anything You Can Do, I Can Do Better: Can Aptamers Replace Antibodies in Clinical Diagnostic Applications?Molecules (Basel, Switzerland) · 2019Review
- In honor of Dr. Donald S. Coffey - Prostate cancer biology and therapy.Asian journal of urology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
Abstract
Antibodies are employed ubiquitously in biomedical sciences, including for diagnostics and therapeutics. One of the most important uses is for immunohistochemical (IHC) staining, a process that has been improving and evolving over decades. IHC is useful when properly employed, yet misuse of the method is widespread and contributes to the "reproducibility crisis" in science. We report some of the common problems encountered with IHC assays, and direct readers to a wealth of literature documenting and providing some solutions to this problem. We also describe a series of vignettes that include our approach to analytical validation of antibodies and IHC assays that have facilitated a number of biological insights into prostate cancer and the refutation of a controversial association of a viral etiology in gliomas. We postulate that a great deal of the problem with lack of accuracy in IHC assays stems from the lack of awareness by researchers for the critical necessity for end-users to validate IHC antibodies and assays in their laboratories, regardless of manufacturer claims or past publications. We suggest that one reason for the pervasive lack of end-user validation for research antibodies is that researchers fail to realize that there are two general classes of antibodies employed in IHC. First, there are antibodies that are "clinical grade" reagents used by pathologists to help render diagnoses that influence patient treatment. Such diagnostic antibodies, which tend to be highly validated prior to clinical implementation, are in the vast minority (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.